Open an account

Viking Therapeutics

VKTX · NASDAQ

$26.71+$1.66 (+6.63%)TodayMarket closed ·
Prev close $25.05

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 59 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Employees
59
Headquarters
San Diego, California
Listed
Apr 29, 2015
Sector
Health Care
Industry
Biotechnology
Website
vikingtherapeutics.com

VKTX key statistics

Market cap
3.20B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.78M
Volume
4.66M
Open price
$25.06
High today
$26.92
Low today
$25.00
52 Week high
$43.15
52 Week low
$24.94

Viking Therapeutics (VKTX) at a glance

Viking Therapeutics (VKTX) last traded at $26.71, with a market cap of 3.20B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $25.00 and $26.92. The current price is 6.8% above the day's low and 0.8% below its high.

Volume so far is 4.66M shares, below the average of 9.78M shares a day.

Over the past year Viking Therapeutics has ranged from $24.94 to $43.15, and now sits 10% of the way up that range.

Viking Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$1.10 per share against an estimate of -$1.27.

The average analyst price target is $99.42, 272.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 20 analystsAvg $99.42
Low
$38.38
Now
$26.71
High
$131.25

VKTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 13.9% on average.

  1. Q3 FY24: reported -$0.22 per share against an estimate of -$0.2569
  2. Q4 FY24: reported -$0.32 per share against an estimate of -$0.2814
  3. Q1 FY25: reported -$0.41 per share against an estimate of -$0.3309
  4. Q2 FY25: reported -$0.58 per share against an estimate of -$0.4553
  5. Q3 FY25: reported -$0.81 per share against an estimate of -$0.6911
  6. Q4 FY25: reported -$1.38 per share against an estimate of -$0.912
  7. Q1 FY26: reported -$1.37 per share against an estimate of -$1.03
  8. Q2 FY26: reported -$1.10 per share against an estimate of -$1.27

VKTX news

  • Press releasePRNewswire

    Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

  • Press releasePRNewswire

    Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

  • Benzinga Bulls and Bears: Costco, KB Home, McDonald’s

  • Piero Cingari

    S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today

  • Avi Kapoor

    Crude Oil Rises Over 4%; Darden Earnings Miss Views

Similar companies

Companies in the same industry as Viking Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.